Matches in SemOpenAlex for { <https://semopenalex.org/work/W2335697542> ?p ?o ?g. }
- W2335697542 endingPage "e145" @default.
- W2335697542 startingPage "e131" @default.
- W2335697542 abstract "Objectives: Remifentanil preconditioning attenuates myocardial ischemia reperfusion injury, but the underlying mechanism is incompletely understood. The Janus activated kinase-2 (JAK2)/signal transducers and activators of transcription-3 (STAT3) and phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathways are critical in both ischemic and pharmacologic preconditioning cardioprotection, which involve the inactivation of glycogen synthase kinase-3β. We hypothesized that remifentanil preconditioning confers cardioprotection via the JAK2/STAT3 and/or PI3K/Akt activation–mediated glycogen synthase kinase-3β inhibition. Design: Pharmacologic intervention. Setting: Research laboratory. Subjects: Male Sprague-Dawley rats. Interventions: In vivo and in vitro treatments. Measurements and Main Results: Male Sprague-Dawley rats (n = 6 per group) were sham operated or subjected to myocardial ischemia reperfusion injury. The JAK2 inhibitor AG490 (3 mg/kg), the PI3K inhibitor wortmannin (15 μg/kg), or the glycogen synthase kinase-3β inhibitor SB216763 (600 μg/kg) were given before inducing in vivo myocardial ischemia reperfusion injury achieved by occluding coronary artery for 30 minutes followed by 120 minutes of reperfusion in the absence or presence of remifentanil preconditioning (6 μg/kg/min). Also, isolated rat hearts were Langendorff perfused and subjected to 30 minutes of global ischemia and 120 minutes of reperfusion without or with remifentanil preconditioning (100 ng/mL) in the presence or absence of AG490 and/or SB216763. Isolated rat cardiomyocytes and H9C2 cells were subjected to hypoxia/reoxygenation alone or in combination with AG490 (100 μM), wortmannin (100 nM), or SB216763 (3 μM) without or with remifentanil preconditioning (2.5 μM). Remifentanil preconditioning reduced postischemic myocardial infarction and hemodynamic dysfunction induced by myocardial ischemia reperfusion injury concomitant with increased phosphorylation of STAT3 at tyr-705 (p-STAT3) and glycogen synthase kinase-3β but not Akt. AG490 but not wortmannin cancelled remifentanil preconditioning cardioprotection, and SB216763 restored it despite the presence of AG490. In Langendorff-perfused hearts, AG490-mediated cancellation of remifentanil preconditioning cardioprotection in attenuating postischemic myocardial infarction and creatinine kinase-MB release was reverted by concomitant administration of SB216763. Remifentanil preconditioning also attenuated posthypoxic cardiomyocyte injury and increased p-STAT3 and glycogen synthase kinase-3β in isolated primary cardiomyocytes and H9C2 cells. STAT3 gene knockdown with specific synthetic RNA cancelled remifentanil preconditioning cardioprotection, whereas glycogen synthase kinase-3β gene knockdown, which per se did not affect STAT3 under hypoxia/reoxygenation condition, preserved remifentanil preconditioning cardioprotection regardless of STAT3 abrogation. Conclusions: Remifentanil preconditioning confers cardioprotection primarily via activation of JAK2/STAT3 signaling that can function independent of PI3K/Akt activation. Glycogen synthase kinase-3β is a critical downstream effector of remifentanil preconditioning cardioprotection." @default.
- W2335697542 created "2016-06-24" @default.
- W2335697542 creator A5003642180 @default.
- W2335697542 creator A5010956113 @default.
- W2335697542 creator A5030600034 @default.
- W2335697542 creator A5044058772 @default.
- W2335697542 creator A5044137903 @default.
- W2335697542 creator A5048882211 @default.
- W2335697542 creator A5075622190 @default.
- W2335697542 creator A5076971720 @default.
- W2335697542 creator A5077325794 @default.
- W2335697542 creator A5081093007 @default.
- W2335697542 date "2016-03-01" @default.
- W2335697542 modified "2023-10-17" @default.
- W2335697542 title "Remifentanil Preconditioning Reduces Postischemic Myocardial Infarction and Improves Left Ventricular Performance via Activation of the Janus Activated Kinase-2/Signal Transducers and Activators of Transcription-3 Signal Pathway and Subsequent Inhibition of Glycogen Synthase Kinase-3β in Rats" @default.
- W2335697542 cites W1596843181 @default.
- W2335697542 cites W1616121322 @default.
- W2335697542 cites W1981403079 @default.
- W2335697542 cites W1982204392 @default.
- W2335697542 cites W1982319740 @default.
- W2335697542 cites W1984670498 @default.
- W2335697542 cites W1985586004 @default.
- W2335697542 cites W1988558923 @default.
- W2335697542 cites W1989499170 @default.
- W2335697542 cites W1991838517 @default.
- W2335697542 cites W1993488931 @default.
- W2335697542 cites W1999517658 @default.
- W2335697542 cites W2001320749 @default.
- W2335697542 cites W2002821724 @default.
- W2335697542 cites W2009306446 @default.
- W2335697542 cites W2013802339 @default.
- W2335697542 cites W2019754771 @default.
- W2335697542 cites W2020428280 @default.
- W2335697542 cites W2028689205 @default.
- W2335697542 cites W2031965306 @default.
- W2335697542 cites W2033665108 @default.
- W2335697542 cites W2040309436 @default.
- W2335697542 cites W2045810271 @default.
- W2335697542 cites W2046982257 @default.
- W2335697542 cites W2053951001 @default.
- W2335697542 cites W2054475515 @default.
- W2335697542 cites W2057319346 @default.
- W2335697542 cites W2059499160 @default.
- W2335697542 cites W2082345834 @default.
- W2335697542 cites W2083010337 @default.
- W2335697542 cites W2086242101 @default.
- W2335697542 cites W2087891654 @default.
- W2335697542 cites W2090281182 @default.
- W2335697542 cites W2099374193 @default.
- W2335697542 cites W2105302664 @default.
- W2335697542 cites W2110287272 @default.
- W2335697542 cites W2112293254 @default.
- W2335697542 cites W2113999599 @default.
- W2335697542 cites W2118087468 @default.
- W2335697542 cites W2126327835 @default.
- W2335697542 cites W2138474912 @default.
- W2335697542 cites W2143914895 @default.
- W2335697542 cites W2145397113 @default.
- W2335697542 cites W2151470941 @default.
- W2335697542 cites W2154247906 @default.
- W2335697542 cites W2157091853 @default.
- W2335697542 cites W2157182219 @default.
- W2335697542 cites W2160086057 @default.
- W2335697542 cites W2161260989 @default.
- W2335697542 cites W2163768568 @default.
- W2335697542 cites W2168325576 @default.
- W2335697542 cites W2241448607 @default.
- W2335697542 cites W2312488124 @default.
- W2335697542 cites W4230837149 @default.
- W2335697542 cites W4317564230 @default.
- W2335697542 doi "https://doi.org/10.1097/ccm.0000000000001350" @default.
- W2335697542 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26468894" @default.
- W2335697542 hasPublicationYear "2016" @default.
- W2335697542 type Work @default.
- W2335697542 sameAs 2335697542 @default.
- W2335697542 citedByCount "35" @default.
- W2335697542 countsByYear W23356975422016 @default.
- W2335697542 countsByYear W23356975422017 @default.
- W2335697542 countsByYear W23356975422018 @default.
- W2335697542 countsByYear W23356975422019 @default.
- W2335697542 countsByYear W23356975422020 @default.
- W2335697542 countsByYear W23356975422021 @default.
- W2335697542 countsByYear W23356975422022 @default.
- W2335697542 countsByYear W23356975422023 @default.
- W2335697542 crossrefType "journal-article" @default.
- W2335697542 hasAuthorship W2335697542A5003642180 @default.
- W2335697542 hasAuthorship W2335697542A5010956113 @default.
- W2335697542 hasAuthorship W2335697542A5030600034 @default.
- W2335697542 hasAuthorship W2335697542A5044058772 @default.
- W2335697542 hasAuthorship W2335697542A5044137903 @default.
- W2335697542 hasAuthorship W2335697542A5048882211 @default.
- W2335697542 hasAuthorship W2335697542A5075622190 @default.
- W2335697542 hasAuthorship W2335697542A5076971720 @default.
- W2335697542 hasAuthorship W2335697542A5077325794 @default.
- W2335697542 hasAuthorship W2335697542A5081093007 @default.
- W2335697542 hasConcept C126322002 @default.
- W2335697542 hasConcept C182996813 @default.
- W2335697542 hasConcept C184235292 @default.